Skanska announces decreased scope for facility in Everett, Washington, USA, worth USD 49M, about SEK 510M
4/12/2024 7:30 AM CET
Press release
Non-regulatory press releases
Skanska announces that Pfizer has reduced the scope of work on its 25,000 square-meter biomanufacturing facility in Everett, Washington, USA, which Skanska previously was contracted to construct. The order reduction amounts to USD 49M, about SEK 510M, which will be deducted from the US order bookings for the first quarter 2024.
The initial contract with Seagen, who recently was acquired by Pfizer, was worth USD 215M, about SEK 2.2 billion, and was announced August 4, 2023.